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ABSTRACT
Purpose: Studies on the expression of epithelial membrane proteins (EMPs) in breast cancer 
have been rare and limited. In the present study, we aimed to evaluate the expression of 
EMP1, EMP2, and EMP3 in invasive ductal carcinoma (IDC) of the breast, and investigate 
their clinical implications.
Methods: In total, 418 IDC cases were collected, and specimens were used to construct a 
tissue microarray. Immunohistochemical staining of EMP1, EMP2, and EMP3 was performed 
and the results were analyzed in combination with the clinical data.
Results: EMP1 was expressed in > 90% of all IDC subtypes. A decreased expression of EMP2 
and EMP3 was observed in triple-negative breast cancer. EMP3 expression was independently 
associated with human epidermal growth factor receptor 2 (HER2) positivity. HER2-negative 
cases exhibited a decreased EMP2 expression along with a higher histological grade and an 
increased proliferative index. No significant difference was found in the overall survival or 
disease-free survival based on the EMP expression. In HER2-negative breast cancer, EMP2 
expression inversely correlated with the histological grade and proliferative index.
Conclusion: EMP2 may be involved in the early stage of tumor development in hormone-
positive breast cancer.
Keywords: Breast neoplasms; EMP-2 protein, human; Immunohistochemistry; Pathology
INTRODUCTION
Breast cancer is the most common carcinoma observed in women. Early detection reveals a 
good prognosis in patients; however, breast cancer is still an aggressive disease that requires 
multidisciplinary therapeutic approaches. Sex steroid hormones, particularly estrogen and 
progesterone, play crucial roles in the development of breast cancer and also serve as targets 
by acting as selective modulators of estrogen receptor (ER) [1]. Moreover, breast cancers 
with an amplified human epidermal growth factor receptor 2 (HER2) can be treated with the 
HER2 targeting agent trastuzumab [2]. The use of preoperative neoadjuvant chemotherapy 
is increasing and it indicates complete pathological response of HER2-positive cancer and 
triple-negative breast cancer (TNBC) in relation to tumor-infiltrating lymphocytes (TIL) 
[3]. As aforementioned, the hormone receptor (HR), HER2, and TIL are major parameters 
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determining the treatment outcome and patient prognosis; however, in addition to these 
known factors, efforts have been made to mine a new prognostic marker and/or potential 
therapeutic target.
Epithelial membrane proteins (EMPs; EMP1, EMP2, and EMP3) belong to the family of 
peripheral myelin protein (PMP22) with highly conserved structural homology. PMP22 is highly 
expressed in peripheral nerves, where it is localized in the compact portion of myelin. It is 
crucial for normal physiological and pathological processes in the peripheral nervous system.
So far, previous studies regarding EMP1, EMP2, and EMP3 demonstrated the variable 
expression of EMPs in diverse solid tumors. In breast cancer, several preclinical and clinical 
studies have been performed; however, these studies investigated only one type of EMP with 
relatively few breast cancer cases without considering the biomarker-defined subtypes [4-7]. 
Since no study has evaluated EMP1, EMP2, and EMP3 in the large number of invasive ductal 
carcinoma (IDC), that is most common histologic type of breast cancer, we aimed to examine 
the expression of EMPs IDC using numerous cases, assess the differential expression of EMPs 
among the IDC subtypes, and correlate the result with clinical parameters.
METHODS
This study was approved by the Institutional Review Board of Severance Hospital, Seoul, 
Korea (No. 4-2018-0429). The need for informed consent was waived by the review board.
Patients
From January 2000 to December 2012, a total of 5,427 patients were diagnosed with breast 
cancer at Severance Hospital, and 1,957 patients received surgical resection. Except 81 
patients who were treated with preoperative neoadjuvant chemotherapy, available 493 cases 
were subjected to tissue microarray (TMA). Among these, 75 cases with core losses were 
excluded, and finally a total of 418 cases from female patients were included. All patients 
underwent treatments according to the standard protocols. All cases were retrospectively 
reviewed by 2 breast pathologists (YJC and JSK) using hematoxylin and eosin (H&E)-stained 
slides. Histological grade was assessed using the Nottingham grading system [8]. Tumor 
staging was based on the 8th American Joint Committee on Cancer criteria.
Disease-free survival (DFS) was calculated from the date of the first curative surgery to the 
date of the first locoregional or systemic relapse or to the date of death without relapse. 
Overall survival (OS) was estimated from the date of the first curative surgery to the date of 
the last follow-up or death from any cause. Clinicopathological parameters evaluated for 
each case included patient age at initial diagnosis, lymph node metastasis, tumor recurrence, 
distant metastasis, and patient survival.
TMA
All H&E-stained slides from resected breast cancer specimens were reviewed and 
representative areas were marked on the slides. Tissue cores (3 mm) were extracted from the 
matched formalin-fixed paraffin-embedded (FFPE) tumor blocks and were placed into 6 × 5 
recipient TMA blocks. Two tumor cores were collected from each case to construct the TMA.
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Immunohistochemical staining and interpretation
Antibodies used in the study for immunohistochemistry (IHC) are listed in Table 1. Briefly, 
3-µm thick tissue sections were cut from the FFPE TMA block. After deparaffinization and 
rehydration using xylene and alcohol graded solutions, respectively, IHC was performed on 
Ventana Discovery XT Automated Slide Stainer (Ventana Medical System, Tucson, USA). Cell 
Conditioning 1 buffer (citrate buffer, pH 6.0; Ventana Medical System) was used for antigen 
retrieval. Appropriate positive and negative controls were included.
Staining of all IHC markers was assessed via light microscopy. A cut-off value of 1% nuclear 
staining or more was considered positive for ER and progesterone receptor (PR) [9]. HER2 
staining was interpreted based on the 2018 American Society of Clinical Oncology/College of 
American Pathologists guidelines [2]. Only strong and circumferential membranous HER2 
expression (3+) was considered positive, whereas 0 and 1+ HER2 staining was regarded as 
negative. Cases with equivocal HER2 expression (2+) were further evaluated for HER-2 gene 
amplification using silver in situ hybridization (SISH). Positive nuclear Ki-67 staining was 
assessed with the positive tumor cell percentage reported as Ki-67 labeling index (LI).
To interpret the EMP1, EMP2, and EMP3 expression, IHC slides were scored by multiplying 
the staining intensity (1, weak; 2, moderate; 3, strong) and the staining proportion score 
(0%, negative; 1, < 30% positive; 2, ≥ 30% positive). Values of 0 and 1 were considered 
negative and those of 2 or more were considered positive [10]. Representative pictures of IHC 
are illustrated in Figure 1.
Tumor classification based on HR and HER2 status
Breast cancer subcategorized was based on biomarker status according to the IHC staining 
results of ER, PR, and HER2 and SISH results for HER2. The specimens were categorized 
as follows: ER and/or PR positive and HER2 negative (HR+HER2−), ER and/or PR positive 
and HER2 overexpressed and/or amplified (HR+HER2+), ER and PR negative and HER2 
overexpressed and/or amplified (HER2), and ER, PR, and HER2 negative (TNBC).
Statistical analysis
Data were analyzed using SPSS software for Windows (version 18.0; SPSS Inc., Chicago, 
USA). A p-value less than 0.05 was considered as statistically significant. Student's t-test and 
Fisher's exact test were used for continuous and categorical variables, respectively. Wilcoxon 
signed rank test was used to evaluate the EMP expression in matched normal and cancer 
tissues within the same core. Kaplan-Meier survival curves and log-rank statistics were used 
to assess the tumor metastasis and survival time. Regression analysis was performed using 
binary logistic analysis.
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Table 1. Source, clone, and dilution of antibodies
Antibody Company Clone Dilution
EMP1 Abcam, Cambridge, UK N-terminal 1:100
EMP2 Abcam, Cambridge, UK C-terminal 1:100
EMP3 Santa Cruz Biotechnology, Santa Cruz, USA SW-5 1:100
EMP = epithelial membrane protein.
RESULTS
Clinicopathological data
In total, 418 cases of female IDC breast cancer were analyzed. Mean patient age was 49.5 
± 11.4 years and median follow-up was 65 months (range, 2–141 months). There were 219 
HR+HER2−, 38 HR+HER2+, 35 HER2, and 126 TNBC cases. Forty-seven patients experienced 
recurrence and the same number of patients died. Base characteristics of patients are 
summarized in Table 2. With respect to the clinicopathological parameters, histological 
388https://ejbc.kr https://doi.org/10.4048/jbc.2020.23.e42






Figure 1. Representative immunohistochemistry of EMP1, EMP2, and EMP3. 
EMP = epithelial membrane protein.
grade (p < 0.001), recurrence (p = 0.008), and death (p = 0.035) significantly differed among 
the breast cancer subtypes. Most of the HR+ cases, irrespective of HER2 status, were of 
histological grade I or II, whereas more than half of HER2 and TNBC cases presented higher 
histological grades (p < 0.001). The HER2 subtype revealed the highest recurrence and death 
rates (p = 0.035; Table 3).
Expression of EMP1, EMP2, and EMP3 in IDC specimens
EMP1 demonstrated > 90% expression in all subtypes and no significant difference was found 
across the subtypes. EMP2 (p < 0.001) and EMP3 (p = 0.009) exhibited decreased expression in 
TNBC compared to that in the other subtypes. EMP2 and EMP3 presented > 80% expression in 
HR+ breast cancers (Table 4).
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Table 2. Base clinicopathological characteristics
Characteristics Value





















Median follow-up period (mo) 65 (2–140.5)
Values are presented as mean ± standard deviation, number (%) or number (range).
HR+ = hormone receptor positive; HER2− = human epidermal growth factor receptor 2 negative; HER2+ = human 
epidermal growth factor receptor 2 positive; TNBC = triple-negative breast cancer.
Table 3. Clinicopathological parameters on the basis of breast invasive ductal carcinoma subtype
Characteristics HR+HER2− (n = 219) HR+HER2+ (n = 38) HER2 (n = 35) TNBC (n = 126) p-value
Histologic grade < 0.001
I 64 (29.2) 5 (13.2) 1 (2.9) 6 (4.8)
II 115 (25.5) 25 (65.8) 16 (45.7) 35 (27.8)
III 40 (18.3) 8 (21.1) 18 (51.4) 85 (67.5)
Lymph node metastasis 91 (41.7) 16 (42.1) 14 (40.0) 44 (35.2) 0.675
Recurrence 14 (6.4) 5 (13.2) 7 (20.0) 21 (16.7) 0.008
Death 17 (7.8) 4 (10.5) 8 (22.9) 18 (14.3) 0.035
Ki67 LI (%) 9.52 ± 11.44 13.08 ± 10.05 12.10 ± 2.05 24.20 ± 2.16 HR+HER2− vs. TNBC, < 0.001*
HR+HER2+ vs. TNBC, < 0.001*
HER2 vs. TNBC, < 0.001*
Values are presented as number (%) or mean ± standard deviation.
HR+ = hormone receptor positive; HER2− = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; 
TNBC = triple-negative breast cancer; LI = labelling index.
*Bonferroni post hoc test.
The histological grade revealed no significant differences in the expression of EMP1, EMP2, 
and EMP3. No significant differences were found for total patients and each subgroup 
(Supplementary Table 1). Univariate logistic regression analysis (Supplementary Table 2) 
revealed that HER2 positivity was significantly associated with EMP2 (odds ratio [OR], 2.164; 
95% confidence interval CI], 1.118–4.188; p = 0.022) and EMP3 expression (OR, 5.213; 95% CI, 
1.590–17.091; p = 0.006). EMP3 positivity was independently associated with HER2 positivity 
(OR, 1.456; 95% CI, 1.272–14.462; p = 0.019).
Markers EMP2 and EMP3 exhibited different expression rates with respect to HER2 
status (Figure 2). Both EMP2 and EMP3 exhibited significantly higher expression rates in 
association with HER2 positivity. In HER2-negative cases with higher histological grades, 
EMP2 expression was significantly decreased (Table 5). Moreover, mean Ki-67 LI was 
significantly higher in the EMP2-negative group among the HER2-negative cases (16.11% ± 
19.59% vs. 24.79% ± 23.09%, respectively, p = 0.001), as listed in Table 5.
EMP2 expression in matched normal, ductal carcinoma in situ (DCIS), and 
invasive carcinoma in HR-positive breast cancer
EMP2 expression in matched normal, DCIS, and invasive cancer were evaluated in the HR-
positive cases (Table 6). EMP2 expression revealed significant stepwise increase from normal 
to DCIS and invasive cancer (p < 0.001). Among the evaluable normal luminal cells in 48 
cases, 17 cases presented weak EMP2 expression (expression score 1 or 2), and 6 cases with 
expression score 2 revealed columnar cell change. Between DCIS and invasive cancer, invasive 
cancer revealed slightly higher expression score compared to DCIS (p = 0.034).
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Table 4. Expression of EMP1, EMP2, and EMP3 in invasive ductal carcinoma on the basis of subtype
Characteristics HR+HER2− (n = 219) HR+HER2+ (n = 38) HER2 (n = 35) TNBC (n = 126) p-value
EMP1 0.762
Negative 7 (3.2) 0 (0.0) 0 (0.0) 3 (2.4)
Positive 212 (96.8) 38 (100.0) 35 (100.0) 123 (97.6)
EMP2 < 0.001
Negative 43 (19.6) 4 (10.5) 8 (22.9) 60 (47.6)
Positive 176 (80.4) 34 (89.5) 27 (77.1) 66 (52.4)
EMP3 0.009
Negative 35 (16.0) 1 (2.6) 2 (5.7) 28 (22.2)
Positive 184 (84.0) 37 (97.4) 33 (94.3) 98 (77.8)
Values are presented as number (%).
HR+ = hormone receptor positive; HER2− = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; 











































































Figure 2. Expression of EMP1, EMP2, and EMP3 on the basis of HER2 status. EMP1 expression does not differ, regardless of HER2 status (A). EMP2 (B) and EMP3 
expression (C) is associated with HER2 positivity. 
EMP = epithelial membrane protein; HER2 = human epidermal growth factor receptor 2.
EMP1, EMP2, and EMP3 expression in IDC and prognosis
For all patients, no significant differences were observed in OS based on EMP1, EMP2, or EMP3 
expression. In HR+HER2− cases, EMP1 and EMP2 positivity exhibited tendencies of better 
OS and DFS; however, these differences were not statistically significant (Figures 3 and 4). In 
HR+HER2− cases with positive EMP3 expression, the patients revealed significantly better 
DFS (p = 0.049; Figure 3). In HR+HER2+ cases, patients presented significantly separated OS 
and DFS in association with EMP3 expression; however, only one patient who exhibited EMP3 
negativity died.
DISCUSSION
In the present study, we evaluated the expression of EMP1, EMP2, and EMP3 in IDC of the 
breast using a numerous HR+HER2− cases and a long follow-up period. We found different 
expression rates of EMP2 and EMP3 according to the HER2 status. In particular, the 
expression of EMP1, EMP2, and EMP3 was reduced in TNBC. We analyzed a relatively large 
number of TNBC cases (n = 126) compared to the previous studies [4,6,11] and found no 
clinical significance in expression of the EMPs; however, HER2 positivity was associated with 
EMP2 and EMP3 expression.
Previous studies have reported that EMP1 downregulation is associated with growth arrest [12] 
and cellular differentiation [13]. Although expression of EMP1 has been reported in glioma 
[14], gastric cancer [15], and acute lymphoid leukemia [16], it has been rarely evaluated in 
breast cancer [5]. Conversely, in nasopharyngeal carcinoma, an inverse correlation exists 
between EMP1 expression and clinical parameters such as T stage, node metastasis, and 
clinical stage [12]. In a previous study that used the ER-positive cell line, MCF7, EMP1 level was 
lower in the cancer epithelium compared to that in normal tissue and the EMP1 expression 
correlated with parameters associated with tumor aggressiveness (T stage, node metastasis, 
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Table 5. Expression of EMPs, histological grade, and proliferative index on the basis of HER2 status
Characteristics EMP1 EMP2 EMP3
Positive Negative p-value Positive Negative p-value Positive Negative p-value
HER2 negative (n = 345)
Histologic grade 0.285 < 0.001 0.652
I (n = 70) 66 (94.3) 4 (5.7) 56 (80.0) 14 (20.0) 58 (82.9) 12 (17.1)
II (n = 150) 147 (98.0) 3 (2.0) 116 (77.3) 34 (22.7) 125 (83.3) 25 (16.7)
III (n = 125) 122 (97.6) 3 (2.4) 70 (56.0) 55 (44.0) 99 (79.2) 26 (20.8)
Ki67 LI (%) 18.74 ± 21.16 17.70 ± 18.01 0.877 16.11 ± 19.59 24.79 ± 23.09 0.001 18.22 ± 20.71 20.90 ± 22.55 0.361
HER2 positive (n = 73)
Histologic grade NA 0.504 0.851
I (n = 6) 6 (100.0) 0 (0.0) 5 (83.3) 1 (16.7) 6 (100.0) 0 (0.0)
II (n = 41) 41 (100.0) 0 (0.0) 36 (87.8) 5 (12.2) 39 (5.1) 2 (4.9)
III (n = 26) 26 (100.0) 0 (0.0) 20 (76.9) 6 (23.1) 25 (96.2) 1 (3.8)
Ki67 LI (%) 15.15 ± 11.23 NA NA 15.90 ± 11.53 11.42 ± 9.05 0.209 15.45 ± 11.37 8.33 ± 2.89 0.286
Values are presented as number (%) or mean ± standard deviation.
EMP = epithelial membrane protein; HER2 = human epidermal growth factor receptor 2; LI = labelling index; NA = not available.
Table 6. EMP2 expression in matched normal, DCIS, and invasive carcinoma in hormone receptor-positive breast cancer
Characteristics Expression score p-value
Normal vs. DCIS (n = 17) 0.65 ± 0.93 vs. 4.00 ± 1.00 < 0.001
Normal vs. invasive carcinoma (n = 48) 0.40 ± 0.76 vs. 3.38 ± 1.54 < 0.001
DCIS vs. invasive carcinoma (n = 58) 3.36 ± 1.33 vs. 3.72 ± 1.47 0.034
Values are presented as mean ± standard deviation.
EMP = epithelial membrane protein; DCIS = ductal carcinoma in situ.
histological grade); however, loss of EMP1 expression correlated with poor OS [5]. The results 
from the study suggested the possibility that EMP1 may act as a negative regulator in ER-
positive breast cancer. In the present study, most of the IDC cases expressed EMP1, particular 
those with HR+, which presented > 90% EMP1 expression. In contrast to the previous study, in 
this study, we did not find any significant difference in the EMP1 expression according to the 
molecular subtype, histological grade, or patient prognosis.
EMP2 is known to be expressed in most human tissues in patterns similar to EMP1 expression 
[17]. A previous study found that EMP2 is involved in cell proliferation and intercellular 
interaction [18]. In solid tumors, particularly endometrial cancer, EMP2 expression increases 
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Figure 3. Overall survival on the basis of EMP1, EMP2, and EMP3 expression and breast cancer subtype. No significance is observed among the EMP1, EMP2, and 
EMP3 expression and breast cancer subtype. The x axis, overall survival (months); y axis, cumulative survival (%). 
HR+ = hormone receptor positive; HER2− = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; 
TNBC = triple-negative breast cancer; EMP = epithelial membrane protein.
in a stepwise manner from hyperplasia to carcinoma [19] and was associated with unfavorable 
patient survival [20]. Fu et al. [4] evaluated 236 IDC specimens and an additional 23 TNBC 
specimens and detected the EMP2 expression in 63% and 70% of IDC and TNBC cases, 
respectively. In contrast, these investigators observed negative or minimal EMP2 expression 
in the normal mammary glands. The level of EMP2 correlates with focal adhesion kinase 
and Src activation and invasion, which are suppressed by blocking EMP2 with an anti-EMP2 
immunoglobulin G1 antibody. Moreover, high EMP2 expression is associated with lymph node 
metastasis, and the authors suggest that EMP2 may act as a therapeutic target for breast cancer, 
specifically in TNBC cases; however, in the present study, we observed decreased expression of 
EMP2 in TNBC cases compared to other subtypes with no significant prognostic differences. 
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Figure 4. Disease-free survival on the basis of EMP1, EMP2, and EMP3 expression and breast cancer subtype. In the HR+HER2− group, EMP3 positive cases depict 
superior disease-free survival. The x axis, disease free survival (months); y axis, cumulative survival (%). 
HR+ = hormone receptor positive; HER2− = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; TNBC = 
triple-negative breast cancer; EMP = epithelial membrane protein.
HER2-negative cases revealed stepwise decreases in the EMP2 expression along with higher 
histological grade and increased proliferative index (Ki-67 LI). Furthermore, we analyzed 
the TNBC cases; however, no significant differences were found in the EMP expression and 
histological grades (data not shown). In the TNBC cases, tumors with histological grade I and 
II exhibited 63.4% EMP2 positivity. The majority of TNBC cases in the present study belonged 
to grade III (67.5%) and presented decreased EMP2 expression. This may explain the different 
results in positive rates between the previous study and the present study as the previous 
study did not report whether EMP2 expression differed among the histological grades. In 
addition to the increased EMP2 protein levels, previous studies using microarray analysis found 
upregulated EMP2 mRNA in breast cancer [21]. In advanced or recurrent breast cancer, EMP2 
gene was detected in the blood sample of the patients [22]. Collectively, our present results in 
accordance with the previous findings suggest that EMP2 might play a crucial role in tumor 
development in hormone-dependent cancers. Although we only evaluated the expression of 
EMPs in IDC specimens without comparable normal tissue, the HR-negative, HER2, and TNBC 
subtypes exhibited decreased expression of EMP2 compared to that in the HR-positive cases. 
This further indirectly supports the involvement of EMP2 in the tumorigenesis of hormone-
dependent cancer. Conversely, we observed decreased expression of EMP2 in the higher 
histologic grade HER2-negative cases, which is not in accordance with the results of previous 
studies. Based on our result and previous studies, EMP2 seems to be mainly involved in the 
early stage of cancer development in HR-positive breast cancer; however, the experimental 
setting and the sample number or sample types differ, and for a concrete conclusion, further 
analysis is required to elucidate the exact role of EMP2 in breast cancer, particularly HR-
positive breast cancer and TNBC. In this study, although few cases could be assessed, in most 
cases, the normal luminal cells lacked EMP2 expression, whereas DCIS and invasive cancer 
cells of HR-positive cases expressed EMP2. Moreover, weak EMP2 expression in columnar cell 
change implies that EMP2 may be involved in early tumorigenesis in HR-positive cancer, as the 
columnar cell change has overlapped genetic alteration of ER-positive low grade lesion such as 
low grade DCIS and tubular carcinoma [23,24].
EMP3 has been studied in several organs and cell lines. In neuroblastoma and gliomas, 
hypermethylation of the EMP3 gene is suggested to play a tumor suppressor role [25]. 
Similarly, in an esophageal squamous cell cancer cell line, EMP3 expression is repressed [26] 
and in non-small cell lung cancer, EMP3 expression is inversely correlated to the TNM stage 
and is reduced compared to that in normal lung tissue [27]. Meanwhile, EMP3 appears to 
be an oncogene in urothelial carcinoma [28] and breast cancer [11]. In breast cancer, EMP3 
mRNA levels are higher than those in normal tissue [7]. Furthermore, EMP3 expression is 
repressed by miR-765, and knockdown of EMP3 inhibits tumor invasion [11]. In the present 
study, EMP3-positivity was presumably related to better DFS in the HR+HER2− group, 
which implied a role for EMP3 as a negative regulator in HR+HER2− IDCs. In a HER2 
overexpressing breast cancer cell line, MYC and EMP3 expression are upregulated, which 
suggests that EMP3 might interact with MYC and may function as an oncogene in HER2-
positive breast cancer [29]. Additionally, we found higher expression of EMP3 in HER2-
positive cases, which was in accordance with the previous results and may support EMP3 as a 
potential therapeutic target in treating HER2 positive breast cancer. Although EMP3 positive 
cases presented significantly better OS and DFS in the HR+HER2+ cases, these results may 
be less reliable as only one EMP3-negative patient was present in the HR+HER2+ group, who 
eventually died. To validate this finding, a larger cohort that includes HER2-positive cases 
with and without HR positivity should be studied to evaluate the effects of EMPs on patients' 
prognosis. Among the HER2-positive cases, the EMP3-positive cases revealed a slightly 
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higher proliferative index than those of the EMP3-negative cases. While this difference in the 
proliferative index was not statistically significant, EMP3 may affect tumor proliferation in 
HER2 positive breast cancer.
The present study has several limitations. First, we used TMA analysis and interpreted the IHC 
results, which might not fully reflect the actual gene expression status. Second, although we 
evaluated the specimens from numerous patients, the number of HER2 cases was relatively 
small, which might be a reason for the insignificant survival curves. Additionally, we only 
analyzed the IDC tissue without evaluating the comparable normal breast tissue, precursor 
lesion like carcinoma in situ, or other histological subtypes of invasive carcinoma. Previous 
studies have evaluated the expression of EMPs in carcinoma and normal tissue and have 
found higher expression of EMPs in carcinoma. As most of the cases (except the TNBC cases) 
presented high positive rates of EMP expression, the result may have context with the previous 
studies, although comparison between IDC subtypes revealed no statistical significance.
In conclusion, EMP1 was highly expressed, and all subtypes of IDC and EMP2 and EMP3 
expression were associated with HER2 positivity. In HER2-negative breast cancer, EMP2 
expression was inversely correlated with the histological grade and proliferative index. EMP2 
may play a crucial role in tumor development in HR-positive breast cancer.
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